Ostrom GT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholz JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(12 suppl 2):iv1–96. https://doi.org/10.1093/neuonc/noaa200.

Article  PubMed  PubMed Central  Google Scholar 

Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381–406. https://doi.org/10.3322/caac.21693.

Article  PubMed  Google Scholar 

Chen DY, Chen CC, Crawford JR, Wang SG. Tumor-related epilepsy: epidemiology, pathogenesis and management. J Neurooncol. 2018;139(1):13–21. https://doi.org/10.1007/s11060-018-2862-0.

Article  PubMed  Google Scholar 

Feyissa AM, Worrell GA, Tatum WO, Chaichana KL, Jentoft ME, Cazares HG, et al. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control. Seizure. 2019;69:283–9. https://doi.org/10.1016/j.seizure.2019.05.018.

Article  PubMed  Google Scholar 

Mastall M, Wolpert F, Gramatzki D, Imbach L, Becker D, Schmick A, et al. Survival of brain tumour patients with epilepsy. Brain. 2021;144(11):3322–7. https://doi.org/10.1093/brain/awab188.

Article  PubMed  Google Scholar 

Seidel S, Wehner T, Miller D, Wellmer J, Schlegel U, Grönheit W. Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication. Neurol Res Pract. 2022;4(1):45. https://doi.org/10.1186/s42466-022-00205-9.

Article  PubMed  PubMed Central  Google Scholar 

Silva M, Vivancox C, Duffau H. The concept of “peritumoral zone” in diffuse low-grade gliomas: oncological and functional implications for a connectome-guided therapeutic attitude. Brain Sci. 2022;12(4):504. https://doi.org/10.3390/brainsci12040504.

Article  PubMed  PubMed Central  Google Scholar 

Huberfeld G, Vecht, CJ. Seizures and gliomas--towards a single therapeutic approach. Nat Rev Neurol. 2016;12(4):204–16. https://doi.org/10.1038/nrneurol.2016.26.

Whitfield B, Huse JT. Classification of adult-type diffuse gliomas: impact of the World Health Organization 2021 update. Brain Pathol. 2022;32(4):e13062. https://doi.org/10.1111/bpa.13062. A comprehensive review of the last WHO classification and its consequences for clinicians.

Article  PubMed  PubMed Central  Google Scholar 

Correia CE, Umemura Y, Flynn JR, Reiner AS, Avila EK. Pharmacoresistant and IDH mutation in low-grade gliomas. Neurooncol Adv. 2021;3(1):vdab146. https://doi.org/10.1093/noajnl/vdab146

van Opijnen MP, Tesileanu CMS, Dirven L, van der Meer PB, Wijnenga MMJ, Vincent APJE, et al. IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas. Neuro Oncol. 2022;16:noac197. https://doi.org/10.1093/neuonc/noac197.

Article  Google Scholar 

Han S, Liu Y, Cai SJ, Qian M, Ding I, Larion M, et al. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122(11):1580–9. https://doi.org/10.1038/s41416-020-0814-x.

Article  PubMed  PubMed Central  Google Scholar 

Winkler F. Understanding epilepsy in IDH-mutated gliomas: towards a targeted therapy. Neuro Oncol. 2022;24(9):1436–7. https://doi.org/10.1093/neuonc/noac122. An interesting comment on the clinical perspectives of the findings reported in Mortazawi et al. (ref 14).

Article  PubMed  Google Scholar 

Mortazawi A, Fayed I, Bachani M, Dowdy T, Jahanipour J, Khan A, et al. IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation. Neuro Oncol. 2022;24(9):1423–35. https://doi.org/10.1093/neuonc/noac003. A highly interesting publication on possible epileptogenic mechanisms in glioma cells.

Article  CAS  Google Scholar 

Giovannini G, Pasini F, Orlandi N, Mirandola L, Meletti S. Tumor-associated status epilepticus in patients with glioma: clinical characteristics and outcomes. Seizure 2016;40:76–80. Epilepsy Behav 2019;101(Pt B):106370. https://doi.org/10.1016/j.yebeh.2019.06.014.

Knudsen-Baas KM, Power KN, Engelsen BA, Hegrestad SE, Gilhus NE, Storstein AM. Status epilepticus secondary to glioma. Seizure. 2016;40:76–80. https://doi.org/10.1016/j.seizure.2016.06.013.

Article  PubMed  Google Scholar 

Walbert T, Hamson RA, Schiff D, Avila EK, Chen M, Kandula P, et al. SNO and EANO practice guideline update: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol. 2021;23(11):1835–44. https://doi.org/10.1093/neuonc/noab152. A consensus statement on seizure prophylaxis in newly diagnosed brain tumor patients, recommending to refrain from primary prophylaxis.

Article  PubMed  PubMed Central  Google Scholar 

Fisher RS, Acevedo C, Arzimanogiou A, Bogacz A, Cross JH, Eiger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–82. https://doi.org/10.1111/epi.12550.

Article  PubMed  Google Scholar 

Seidel S, Wehner T, Miller D, Wellmer J, Schlegel U, Gronheit W. Brain tumor related epilepsy: pathophysiological approaches and rational management of antiseizure medication. Neurol Res Pract. 2022;4(1):45. https://doi.org/10.1186/s42466-022-00205-9. Excellent update on therapeutics options in brain tumor epilepsy.

Article  PubMed  PubMed Central  Google Scholar 

Van der Meer PB, Koekkoek JAF, van den Bent MJ, Direvn L, Taphoorn MJB. Effect of antiepileptic drugs in glioma patients on self-reported depression, anxiety, and cognitive complaints. J Neurooncol. 2021;153(1):89–98. https://doi.org/10.1007/s11060-021-03747. A multicenter cross-sectional study of the relationship between antiepileptics and psychiatric symptoms, concluding that antiepileptics are not independently associated with such symptoms.

Article  PubMed  PubMed Central  Google Scholar 

van der Meer PB, Dirven L, van den Bent MJ, Preusser M, Taphoorn MJB, Ruda R, et al. Prescription preferences of antiepileptic drugs in brain tumor patients: an international survey among EANO members. Neurooncol Pract. 2021;9(2):105–13. https://doi.org/10.1093/nop/npab059.eCollection2022Apr.

Article  PubMed  PubMed Central  Google Scholar 

Van der Meer PB, Dirven L, Fiocco M, Vos MJ, Kouwenhoven MCM, van den Bent MJ, et al. First-line antiepileptic drug treatment in glioma patients with epilepsy: levetiracetam vs valproic acid. Epilepsia. 2021;62(5):1119–29. https://doi.org/10.1111/epi.1688.

Article  PubMed  PubMed Central  Google Scholar 

Knudsen-Baas KM, Johannessen TB, Myklebust TÅ, Aarseth JH, Owe JF, Gilhus NE, et al. Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV. J Neurooncol. 2018;140(3):739–48. https://doi.org/10.1007/s11060-018-03007-9.

Article  CAS  PubMed  Google Scholar 

De Bruin ME, van der Meer PB, Dirven L, Taphoorn M, Koekkoek JAF. Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review. Neurooncol Pract. 2021;8(5):501–17. https://doi.org/10.1093/nop/npab030.

Article  PubMed  PubMed Central  Google Scholar 

Mo F, Meletti S, Belcastro V, Quadri S, Napolitano M, Bello L, et al. Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study. J Neurooncol. 2022;157(3):551–9. https://doi.org/10.1007/s11060-022-03998-6.

Article  CAS  PubMed  Google Scholar 

Van Opijnen MP, van der Meer PB, Dirven L, Fiocco M, Kouwenhoven MCM, van den Bent MJ, et al. The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide. J Neurooncol. 2021;154(1):73–81. https://doi.org/10.1007/s11060-021-03800-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maschio M, Sperati F, Dinapoli L, Vidiri A, Fabi A, Pace A, et al. Weight of epilepsy in brain tumor patients. J Neurooncol. 2014;118(2):385–93. https://doi.org/10.1007/s11060-014-1449-7.

Article  PubMed  Google Scholar 

Maschio M. Brain tumor-related epilepsy 2012. Curr Neuropharmacol. 2012;10(2):124–33. https://doi.org/10.2174/157015912800604470.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maschio M, Maialetti A, Mocellini C, Domina E, Pauletto G, Costa C, et al. Effect of brivaracetam on efficacy and tolerability in patients with brain tumor-related epilepsy: a retrospective multicenter study. Front Neurol. 2020;19(11):813. https://doi.org/10.3389/fneur.2020.00813.

Article  Google Scholar 

Lange F, Hörnschemeyer J, Kirschstein T. Glutamatergic mechanisms in glioblastoma and tumor-associated epilepsy. Cells. 2021;10(5):1226. https://doi.org/10.3390/cells10051226.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maschio M, Zarabla A, Maialetti A, Fabi A, Vidiri A, Villani V, et al. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: a prospective explorative study with a historical control group. Epilepsy Behav. 2017;73:83–9. https://doi.org/10.1016/j.yebeh.2017.05.031.

Article  PubMed  Google Scholar 

Ruda R, Houillier C, Maschio M, Reijneveld J, Hellot S, De Backer M, et al. Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: results from a prospective, noninterventional study in European clinical practice (VIBES). Epilepsia. 2020;61(4):647–56. https://doi.org/10.1111/epi.16486.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Meer PB, Taphoorn MJB, Koekkoek JAF. Management of epilepsy in brain tumor patients. Curr Opin Oncol. 2022;34(6):685–90. https://doi.org/10.1097/CCO.0000000000000876.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang H, Deng G, Liu B, Cheng J, Li Y, Tan Y, et al. Analysis of the short-term outcomes and risk factors of seizure relapse in patients with gliomas after antiepileptic drugs withdrawal. J Clin Neurosci. 2020;82(Pt A):20–5. https://doi.org/10.1016/j.jocn.2020.09.051.

Article  CAS  PubMed  Google Scholar 

Koekkoek JAF, Dirven L, Taphoorn MJB. The withdrawal of antiepileptic drugs in patients with low-grade and anaplastic glioma. Expert Rev Neurother. 2017;17(2):193–202. https://doi.org/10.1080/14737175.2016.1219250.

Article  CAS  PubMed  Google Scholar 

Kerkhof M, Koekkoek JAF, Vos MJ, van den Bent MJ, Taal W, Postma TJ, et al. Withdrawal of antiepileptic drugs in patients with low grade and anaplastic glioma after long-term seizure freedom: a prospective observational study. J Neurooncol. 2019;142(3):463–70. https://doi.org/10.1007/s11060-019-03117-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huan VOA, Ambady P, Spencer D. The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma. Epilepsy Behav Rep. 2022;29(18):10052. https://doi.org/10.1016/j.ebr.2022.100526.